Breaking News Instant updates and real-time market news.

AMGN

Amgen

$183.94

-1.02 (-0.55%)

09:02
06/19/18
06/19
09:02
06/19/18
09:02

Amgen granted marketing authorization for BLINCYTO by European Commission

Amgen announced that the European Commission, or EC, has granted a full marketing authorization for BLINCYTO, or blinatumomab, based on the overall survival, or OS, data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or ALL. "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit over standard of care," said David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen. "For decades, overall survival has been the gold standard for assessing the efficacy of treatments for blood cancers. The near doubling of median overall survival versus standard of care seen in the TOWER study is groundbreaking and reinforces BLINCYTO as a highly effective ALL therapy, providing physicians with a much needed, efficacious treatment option, potentially offering patients the chance to live longer."

AMGN Amgen
$183.94

-1.02 (-0.55%)

06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/05/18
JEFF
06/05/18
NO CHANGE
Target $200
JEFF
Buy
Jefferies thesis on Amgen unchanged after Mylan biosimilar approval
Jefferies analyst Michael Yee says the approval of Mylan's (MYL) Neulasta biosimilar is a headline risk factor for Amgen (AMGN) but does not change his thesis on the latter as consensus already knew a biosimilar was coming. The Street models some Neulasta decline already and Amgen's multi-year low price-to-earnings multiple reflects some of this, Yee tells investors in a research note. He keeps a Buy rating on Amgen shares with a $200 price target.

TODAY'S FREE FLY STORIES

YUM

Yum! Brands

$88.81

-0.52 (-0.58%)

20:41
10/23/18
10/23
20:41
10/23/18
20:41
Downgrade
Yum! Brands rating change  »

Yum! Brands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

WING

Wingstop

$69.62

-0.48 (-0.68%)

20:38
10/23/18
10/23
20:38
10/23/18
20:38
Downgrade
Wingstop rating change  »

Wingstop downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BJRI

BJ's Restaurants

$65.49

-1.4 (-2.09%)

20:35
10/23/18
10/23
20:35
10/23/18
20:35
Downgrade
BJ's Restaurants rating change  »

BJ's Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

  • 06

    Nov

AMSSY

AMS AG

$0.00

(0.00%)

20:34
10/23/18
10/23
20:34
10/23/18
20:34
Downgrade
AMS AG rating change  »

AMS AG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.60

0.185 (2.20%)

20:25
10/23/18
10/23
20:25
10/23/18
20:25
Hot Stocks
Ford names Anning Chen the new head of China business »

Earlier today, Ford…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 13

    Dec

T

AT&T

$33.03

0.37 (1.13%)

, BA

Boeing

$349.74

-6.24 (-1.75%)

20:25
10/23/18
10/23
20:25
10/23/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$33.03

0.37 (1.13%)

BA

Boeing

$349.74

-6.24 (-1.75%)

UPS

UPS

$114.22

-1.38 (-1.19%)

TMO

Thermo Fisher

$223.46

-2.29 (-1.01%)

GD

General Dynamics

$187.80

-2.26 (-1.19%)

NOC

Northrop Grumman

$304.17

-2.6 (-0.85%)

BSX

Boston Scientific

$36.03

-0.6 (-1.64%)

NSC

Norfolk Southern

$156.94

-7 (-4.27%)

ITW

Illinois Tool Works

$126.51

-0.89 (-0.70%)

SIRI

Sirius XM

$5.96

-0.06 (-1.00%)

HLT

Hilton

$68.89

-1.28 (-1.82%)

FCX

Freeport McMoRan

$11.61

-0.395 (-3.29%)

QSR

Restaurant Brands

$56.80

0.15 (0.26%)

NDAQ

Nasdaq

$81.73

0.72 (0.89%)

IVZ

Invesco

$21.18

0.06 (0.28%)

OC

Owens Corning

$47.46

-1.26 (-2.59%)

NYCB

New York Community Bancorp

$9.41

0.03 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Dec

NDLS

Noodles & Company

$12.70

0.11 (0.87%)

20:12
10/23/18
10/23
20:12
10/23/18
20:12
Conference/Events
Noodles & Company participates in a conference call with Jefferies »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

LIQT

LiqTech

$1.31

-0.01 (-0.76%)

20:02
10/23/18
10/23
20:02
10/23/18
20:02
Conference/Events
LiqTech to host conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

19:45
10/23/18
10/23
19:45
10/23/18
19:45
General news
Breaking General news story  »

Kansas City Federal…

FBMS

First Bancshares

$35.68

-0.53 (-1.46%)

19:36
10/23/18
10/23
19:36
10/23/18
19:36
Earnings
First Bancshares reports Q3 adjusted EPS 62c, consensus 60c »

Reports Q3 NII $21.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTI

Proteostasis

$7.39

0.22 (3.07%)

19:30
10/23/18
10/23
19:30
10/23/18
19:30
Syndicate
Proteostasis 11M share Secondary priced at $6.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

NCOM

National Commerce

$37.80

0.38 (1.02%)

19:19
10/23/18
10/23
19:19
10/23/18
19:19
Earnings
National Commerce reports Q3 EPS 59c, consensus 63c »

"We are pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Dec

ON

ON Semiconductor

$16.09

0.21 (1.32%)

19:14
10/23/18
10/23
19:14
10/23/18
19:14
Hot Stocks
ON Semiconductor announces CE certification for Sigfox RF solution »

ON Semiconductor has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 08

    May

LPT

Liberty Property

$41.51

1.285 (3.19%)

, CMCSA

Comcast

$35.63

-0.12 (-0.34%)

19:10
10/23/18
10/23
19:10
10/23/18
19:10
Recommendations
Liberty Property, Comcast analyst commentary  »

Liberty Property price…

LPT

Liberty Property

$41.51

1.285 (3.19%)

CMCSA

Comcast

$35.63

-0.12 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 07

    Nov

MANH

Manhattan Associates

$47.61

-0.36 (-0.75%)

, RRC

Range Resources

$16.46

-0.24 (-1.44%)

18:55
10/23/18
10/23
18:55
10/23/18
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

MANH

Manhattan Associates

$47.61

-0.36 (-0.75%)

RRC

Range Resources

$16.46

-0.24 (-1.44%)

TER

Teradyne

$32.20

-0.09 (-0.28%)

TSS

TSYS

$92.62

-0.85 (-0.91%)

NAVI

Navient

$12.40

-0.13 (-1.04%)

COF

Capital One

$87.12

-1.5 (-1.69%)

JNPR

Juniper

$27.37

-1.11 (-3.90%)

RHI

Robert Half

$64.01

0.63 (0.99%)

CMTA

Clementia Pharmaceuticals

$10.00

0.41 (4.28%)

APC

Anadarko

$61.84

-2.1 (-3.28%)

COG

Cabot Oil & Gas

$22.72

-0.44 (-1.90%)

AKRX

Akorn

$6.47

-0.12 (-1.82%)

IIVI

II-VI

$38.01

-0.44 (-1.14%)

NDLS

Noodles & Company

$12.70

0.11 (0.87%)

MKSI

MKS Instruments

$73.35

-1.13 (-1.52%)

IRBT

iRobot

$91.69

0.91 (1.00%)

CSL

Carlisle

$102.37

-0.64 (-0.62%)

TXN

Texas Instruments

$100.25

0.51 (0.51%)

EW

Edwards Lifesciences

$148.31

-1.175 (-0.79%)

AI

Arlington Asset Investment

$8.34

-0.07 (-0.83%)

UMBF

UMB Financial

$62.37

-1.32 (-2.07%)

FCF

First Commonwealth

$14.66

0.245 (1.70%)

VAR

Varian Medical

$104.27

-0.24 (-0.23%)

QEP

QEP Resources

$9.74

-0.52 (-5.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 31

    Oct

  • 01

    Nov

  • 09

    Nov

  • 25

    Oct

BLK

BlackRock

$387.58

-4.76 (-1.21%)

, ISNPY

Intesa Sanpaolo

$0.00

(0.00%)

18:51
10/23/18
10/23
18:51
10/23/18
18:51
Periodicals
BlackRock cools on buying Intesa asset management unit stake, Bloomberg says »

BlackRock's (BLK)…

BLK

BlackRock

$387.58

-4.76 (-1.21%)

ISNPY

Intesa Sanpaolo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PAAS

Pan American Silver

$15.09

-0.19 (-1.24%)

18:50
10/23/18
10/23
18:50
10/23/18
18:50
Hot Stocks
Pan American Silver announces major discovery at La Colorada in Mexico »

Pan American Silver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

PFE

Pfizer

$44.09

-0.28 (-0.63%)

, LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

18:42
10/23/18
10/23
18:42
10/23/18
18:42
Hot Stocks
Pfizer, Eli Lilly: Phase 3 study of tanezumab met all three co-primary endpoints »

Pfizer (PFE) and Eli…

PFE

Pfizer

$44.09

-0.28 (-0.63%)

LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

EXPI

eXp World Holdings

$12.11

-0.39 (-3.12%)

18:31
10/23/18
10/23
18:31
10/23/18
18:31
Hot Stocks
eXp World Holdings signs LOI to acquire VirBELA, terms not disclosed »

eXp World Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

IIVI

II-VI

$38.01

-0.44 (-1.14%)

18:26
10/23/18
10/23
18:26
10/23/18
18:26
Initiation
II-VI initiated at DA Davidson »

II-VI initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XOM

Exxon Mobil

$79.83

-1.32 (-1.63%)

, CVX

Chevron

$113.41

-3.82 (-3.26%)

18:22
10/23/18
10/23
18:22
10/23/18
18:22
Periodicals
Endeavor Energy explores possible sale of company, WSJ reports »

Endeavor Energy Resources…

XOM

Exxon Mobil

$79.83

-1.32 (-1.63%)

CVX

Chevron

$113.41

-3.82 (-3.26%)

BP

BP

$42.30

-0.855 (-1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

VMI

Valmont

$127.55

-1.68 (-1.30%)

18:09
10/23/18
10/23
18:09
10/23/18
18:09
Hot Stocks
Breaking Hot Stocks news story on Valmont »

Valmont lowers FY18 free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

VMI

Valmont

$127.55

-1.68 (-1.30%)

18:08
10/23/18
10/23
18:08
10/23/18
18:08
Earnings
Valmont lowers FY18 EPS view to $7.50-$7.65 from $7.55-$7.65, consensus $7.58 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

VMI

Valmont

$127.55

-1.68 (-1.30%)

18:06
10/23/18
10/23
18:06
10/23/18
18:06
Earnings
Valmont reports Q3 adjusted EPS $1.82, consensus $1.71 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

NWE

NorthWestern

$59.47

-0.79 (-1.31%)

18:04
10/23/18
10/23
18:04
10/23/18
18:04
Earnings
NorthWestern reports Q3 adjusted EPS 58c, consensus 72c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.